Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of ONO-7268MX2 in hepatocellular carcinoma
jRCT2080222427Phase 1
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2014
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, single-arm trial of ONO-7268MX2 in hepatocellular carcinoma (HCC), sponsored by Ono Pharmaceutical.
02
Drugs
ONO-7268MX2
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080222427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222427.